When developing a CAR-T oncology therapy, common failures in late-preclinical and clinical stages can be attributed to early discovery activities. Common challenges include:
- Selecting ‘bad actor’ hits that are not developable/cause tonic signaling
- Optimizing specificity to avoid off-target effects/immune cell activation
- Ensuring cross-reactivity in your tox species (mouse, rat, NHP)
- Understanding on-target/off-tumor risks and other safety liabilities in functional in vitro studies
Learn how to avoid common pitfalls and how our expertise can help guide your program to success.